{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:50:17Z","timestamp":1792108217878,"version":"4.4.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100031315","name":"AstraZeneca UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031315","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["GM114179, GM146097"],"award-info":[{"award-number":["GM114179, GM146097"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI138195"],"award-info":[{"award-number":["AI138195"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA246785, R01CA256928, and R01CA275967"],"award-info":[{"award-number":["R01CA246785, R01CA256928, and R01CA275967"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["P30HD106451"],"award-info":[{"award-number":["P30HD106451"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Adeno-associated virus (AAV) mediated monoclonal antibody (mAb) expression in the central nervous system (CNS) constitutes a promising approach for treating various CNS disorders. However, a comprehensive understanding of AAV biodistribution and antibody expression in the brain following viral vector administration via different local CNS routes and systemic administration is not well established. AAV9 and AAV5 vectors encoding antibody against a protein associated with neurodegeneration (i.e., anti-Target-X mAb), as well as AAV9 encoding a control antibody (Ctrl-mAb), were administered to rats via intravenous (IV), intra-cisterna magna (ICM), and intrastriatal (IST) routes. Effect of immunosuppression regimen was also investigated. Blood\/plasma concentrations of the vector and mAb were measured at day 21 and day 56, the latter only for ICM group. AAV and mAb concentrations in different brain regions, interstitial fluid (ISF), cerebrospinal fluid (CSF), and some peripheral tissues were analyzed. Both the IST and ICM routes showed dose-proportional, and higher vector biodistribution and mAb expression in the brain compared to the IV route. Twenty-fold lower AAV dose administered via IST route produced similar transgene expression higher dose administered via ICM route. Non-immunosuppressed rats exhibited a sharp decline in mAb plasma concentration after 2nd week and lower brain and tissue homogenate concentrations at 3-week. IST and ICM administration of AAV results in higher and more sustained expression of antibody in the brain compared to IV delivery, particularly when immune responses are controlled using concomitant immunosuppression regimen.<\/jats:p>","DOI":"10.1007\/s10928-026-10050-x","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:15:35Z","timestamp":1784117735000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Differential expression of monoclonal antibody in rat brain following systemic and local administration of AAV"],"prefix":"10.1007","volume":"53","author":[{"given":"Ekram Ahmed","family":"Chowdhury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Meno-Tetang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navya","family":"Desireddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Jerez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leeha","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneesh","family":"Rajwade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidhaarth","family":"Bulusu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanguy","family":"Jamier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Nucitelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Cusdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Dobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhaval K.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"10050_CR1","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.addr.2021.01.017","volume":"170","author":"EA Chowdhury","year":"2021","unstructured":"Chowdhury EA, Meno-Tetang G, Chang HY, Wu S, Huang HW, Jamier T et al (2021) Current progress and limitations of AAV mediated delivery of protein therapeutic genes and the importance of developing quantitative pharmacokinetic\/pharmacodynamic (PK\/PD) models. Adv Drug Deliv Rev 170:214\u2013237","journal-title":"Adv Drug Deliv Rev"},{"key":"10050_CR2","doi-asserted-by":"publisher","first-page":"14051","DOI":"10.1038\/mtm.2014.51","volume":"1","author":"C Hinderer","year":"2014","unstructured":"Hinderer C, Bell P, Vite CH, Louboutin JP, Grant R, Bote E et al (2014) Widespread gene transfer in the central nervous system of cynomolgus macaques following delivery of AAV9 into the cisterna magna. Mol Ther Methods Clin Dev 1:14051","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"10050_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/gt.2009.113","volume":"17","author":"YQ Xue","year":"2010","unstructured":"Xue YQ, Ma BF, Zhao LR, Tatom JB, Li B, Jiang LX et al (2010) AAV9-mediated erythropoietin gene delivery into the brain protects nigral dopaminergic neurons in a rat model of Parkinson\u2019s disease. Gene Ther 17(1):83\u201394","journal-title":"Gene Ther"},{"issue":"4","key":"10050_CR4","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/gt.2012.101","volume":"20","author":"SJ Gray","year":"2013","unstructured":"Gray SJ, Nagabhushan Kalburgi S, McCown TJ, Jude Samulski R (2013) Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther 20(4):450\u2013459","journal-title":"Gene Ther"},{"key":"10050_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-020-0178-0","author":"KL Pietersz","year":"2020","unstructured":"Pietersz KL, Martier RM, Baatje MS, Liefhebber JM, Brouwers CC, Pouw SM et al (2020) Transduction patterns in the CNS following various routes of AAV-5-mediated gene delivery. Gene Ther. https:\/\/doi.org\/10.1038\/s41434-020-0178-0","journal-title":"Gene Ther"},{"key":"10050_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11020129","author":"EA Spronck","year":"2021","unstructured":"Spronck EA, Valles A, Lampen MH, Montenegro-Miranda PS, Keskin S, Heijink L et al (2021) Intrastriatal administration of AAV5-miHTT in non-human primates and rats is well tolerated and results in miHTT transgene expression in key areas of Huntington disease pathology. Brain Sci. https:\/\/doi.org\/10.3390\/brainsci11020129","journal-title":"Brain Sci"},{"key":"10050_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-022-00346-1","author":"J Chandran","year":"2022","unstructured":"Chandran J, Chowdhury EA, Perkinton M, Jamier T, Sutton D, Wu S et al (2022) Assessment of AAV9 distribution and transduction in rats after administration through intrastriatal, intracisterna magna and lumbar intrathecal routes. Gene Ther. https:\/\/doi.org\/10.1038\/s41434-022-00346-1","journal-title":"Gene Ther"},{"key":"10050_CR8","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.omtm.2020.04.001","volume":"17","author":"K Bey","year":"2020","unstructured":"Bey K, Deniaud J, Dubreil L, Joussemet B, Cristini J, Ciron C et al (2020) Intra-CSF AAV9 and AAVrh10 administration in nonhuman primates: promising routes and vectors for which neurological diseases? Mol Ther Methods Clin Dev 17:771\u201384","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10050_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2020.146832","volume":"1739","author":"RM Bailey","year":"2020","unstructured":"Bailey RM, Rozenberg A, Gray SJ (2020) Comparison of high-dose intracisterna magna and lumbar puncture intrathecal delivery of AAV9 in mice to treat neuropathies. Brain Res 1739:146832","journal-title":"Brain Res"},{"issue":"7","key":"10050_CR10","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1089\/hum.2018.233","volume":"30","author":"Z Chai","year":"2019","unstructured":"Chai Z, Zhang X, Dobbins AL, Rigsbee KM, Wang B, Samulski RJ et al (2019) Optimization of Dexamethasone Administration for Maintaining Global Transduction Efficacy of Adeno-Associated Virus Serotype 9. Hum Gene Ther 30(7):829\u2013840","journal-title":"Hum Gene Ther"},{"key":"10050_CR11","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.omtm.2018.02.005","volume":"9","author":"RM Bailey","year":"2018","unstructured":"Bailey RM, Armao D, Nagabhushan Kalburgi S, Gray SJ (2018) Development of Intrathecal AAV9 Gene Therapy for Giant Axonal Neuropathy. Mol Ther Methods Clin Dev 9:160\u2013171","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"3","key":"10050_CR12","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/mt.2014.210","volume":"23","author":"K Meyer","year":"2015","unstructured":"Meyer K, Ferraiuolo L, Schmelzer L, Braun L, McGovern V, Likhite S et al (2015) Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates. Mol Ther 23(3):477\u201387","journal-title":"Mol Ther"},{"issue":"8","key":"10050_CR13","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/gt.2011.130","volume":"19","author":"T Federici","year":"2012","unstructured":"Federici T, Taub JS, Baum GR, Gray SJ, Grieger JC, Matthews KA et al (2012) Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs. Gene Ther 19(8):852\u2013859","journal-title":"Gene Ther"},{"issue":"7\u20138","key":"10050_CR14","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41434-020-0178-0","volume":"28","author":"KL Pietersz","year":"2021","unstructured":"Pietersz KL, Martier RM, Baatje MS, Liefhebber JM, Brouwers CC, Pouw SM et al (2021) Transduction patterns in the CNS following various routes of AAV-5-mediated gene delivery. Gene Ther 28(7\u20138):435\u2013446","journal-title":"Gene Ther"},{"key":"10050_CR15","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.neures.2014.09.002","volume":"93","author":"A Watakabe","year":"2015","unstructured":"Watakabe A, Ohtsuka M, Kinoshita M, Takaji M, Isa K, Mizukami H et al (2015) Comparative analyses of adeno-associated viral vector serotypes 1, 2, 5, 8 and 9 in marmoset, mouse and macaque cerebral cortex. Neurosci Res 93:144\u2013157","journal-title":"Neurosci Res"},{"key":"10050_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2023.10.005","author":"S Liu","year":"2023","unstructured":"Liu S, Chowdhury EA, Xu V, Jerez A, Mahmood M, Ly BQ et al (2023) Whole-body disposition and physiologically based pharmacokinetic modeling of adeno-associated viruses and the transgene product. J Pharm Sci. https:\/\/doi.org\/10.1016\/j.xphs.2023.10.005","journal-title":"J Pharm Sci"},{"key":"10050_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2023.08.023","author":"EA Chowdhury","year":"2023","unstructured":"Chowdhury EA, Ahuja M, Wu S, Liu S, Huang HW, Kumar M et al (2023) Pharmacokinetics of AAV9 mediated trastuzumab expression in rat brain following systemic and local administration. J Pharm Sci. https:\/\/doi.org\/10.1016\/j.xphs.2023.08.023","journal-title":"J Pharm Sci"},{"key":"10050_CR18","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.omtm.2019.09.006","volume":"15","author":"C Wang","year":"2019","unstructured":"Wang C, Mulagapati SHR, Chen Z, Du J, Zhao X, Xi G et al (2019) Developing an Anion Exchange Chromatography Assay for Determining Empty and Full Capsid Contents in AAV6.2. Mol Ther Methods Clin Dev 15:257\u2013263","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"6","key":"10050_CR19","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1080\/19420862.2018.1473910","volume":"10","author":"HY Chang","year":"2018","unstructured":"Chang HY, Morrow K, Bonacquisti E, Zhang W, Shah DK (2018) Antibody pharmacokinetics in rat brain determined using microdialysis. MAbs 10(6):843\u2013853","journal-title":"MAbs"},{"key":"10050_CR20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.omtm.2017.01.003","volume":"4","author":"VM Velazquez","year":"2017","unstructured":"Velazquez VM, Meadows AS, Pineda RJ, Camboni M, McCarty DM, Fu H (2017) Effective Depletion of Pre-existing Anti-AAV Antibodies Requires Broad Immune Targeting. Mol Ther Methods Clin Dev 4:159\u2013168","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10050_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61779-111-6_2","volume-title":"Neuroproteomics","author":"S Spijker","year":"2011","unstructured":"Spijker S (2011) Dissection of Rodent Brain Regions. In: Li KW (ed) Neuroproteomics, vol 57. Springer Science"},{"issue":"1","key":"10050_CR22","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.xphs.2020.05.025","volume":"110","author":"HP Chang","year":"2021","unstructured":"Chang HP, Kim SJ, Shah DK (2021) Whole-Body Pharmacokinetics of Antibody in Mice Determined using Enzyme-Linked Immunosorbent Assay and Derivation of Tissue Interstitial Concentrations. J Pharm Sci 110(1):446\u2013457","journal-title":"J Pharm Sci"},{"key":"10050_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-0718-2","volume-title":"Techniques and methodological approaches in breast cancer research","author":"J Russo","year":"2014","unstructured":"Russo J, Russo IH (2014) Techniques and methodological approaches in breast cancer research. Springer, New York"},{"issue":"11","key":"10050_CR24","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1124\/dmd.117.076414","volume":"45","author":"AP Singh","year":"2017","unstructured":"Singh AP, Shah DK (2017) Measurement and Mathematical Characterization of Cell-Level Pharmacokinetics of Antibody-Drug Conjugates: A Case Study with Trastuzumab-vc-MMAE. Drug Metab Dispos 45(11):1120\u20131132","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10050_CR25","doi-asserted-by":"publisher","first-page":"297","DOI":"10.4161\/mabs.23684","volume":"5","author":"DK Shah","year":"2013","unstructured":"Shah DK, Betts AM (2013) Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human. MAbs 5(2):297\u2013305","journal-title":"MAbs"},{"issue":"1","key":"10050_CR26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12987-018-0113-6","volume":"15","author":"SB Hladky","year":"2018","unstructured":"Hladky SB, Barrand MA (2018) Elimination of substances from the brain parenchyma: efflux via perivascular pathways and via the blood-brain barrier. Fluids Barriers CNS 15(1):30","journal-title":"Fluids Barriers CNS"},{"issue":"3","key":"10050_CR27","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10928-013-9301-9","volume":"40","author":"EC de Lange","year":"2013","unstructured":"de Lange EC (2013) Utility of CSF in translational neuroscience. J Pharmacokinet Pharmacodyn 40(3):315\u2013326","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"3","key":"10050_CR28","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s00401-018-1812-4","volume":"135","author":"NJ Abbott","year":"2018","unstructured":"Abbott NJ, Pizzo ME, Preston JE, Janigro D, Thorne RG (2018) The role of brain barriers in fluid movement in the CNS: is there a \u2018glymphatic\u2019 system? Acta Neuropathol 135(3):387\u2013407","journal-title":"Acta Neuropathol"},{"key":"10050_CR29","doi-asserted-by":"crossref","unstructured":"Chowdhury EA, Noorani B, Alqahtani F, Bhalerao A, Raut S, Sivandzade F et al (2021) Understanding the brain uptake and permeability of small molecules through the BBB: A technical overview. J Cereb Blood Flow Metab. :271678X20985946","DOI":"10.1177\/0271678X20985946"},{"issue":"3","key":"10050_CR30","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10928-019-09639-2","volume":"46","author":"Z Li","year":"2019","unstructured":"Li Z, Shah DK (2019) Two-pore physiologically based pharmacokinetic model with de novo derived parameters for predicting plasma PK of different size protein therapeutics. J Pharmacokinet Pharmacodyn 46(3):305\u2013318","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"10050_CR31","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10928-019-09641-8","volume":"46","author":"HY Chang","year":"2019","unstructured":"Chang HY, Wu S, Meno-Tetang G, Shah DK (2019) A translational platform PBPK model for antibody disposition in the brain. J Pharmacokinet Pharmacodyn 46(4):319\u201338","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"9","key":"10050_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076310","volume":"8","author":"DF Aschauer","year":"2013","unstructured":"Aschauer DF, Kreuz S, Rumpel S (2013) Analysis of transduction efficiency, tropism and axonal transport of AAV serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain. PLoS One 8(9):e76310","journal-title":"PLoS One"},{"issue":"6","key":"10050_CR33","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1093\/biolre\/ioz040","volume":"100","author":"Y Seita","year":"2019","unstructured":"Seita Y, Tsukiyama T, Azami T, Kobayashi K, Iwatani C, Tsuchiya H et al (2019) Comprehensive evaluation of ubiquitous promoters suitable for the generation of transgenic cynomolgus monkeysdagger. Biol Reprod 100(6):1440\u20131452","journal-title":"Biol Reprod"},{"key":"10050_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.685802","volume":"12","author":"DJ Finneran","year":"2021","unstructured":"Finneran DJ, Njoku IP, Flores-Pazarin D, Ranabothu MR, Nash KR, Morgan D et al (2021) Toward development of neuron specific transduction after systemic delivery of viral vectors. Front Neurol 12:685802","journal-title":"Front Neurol"},{"issue":"6","key":"10050_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198154","volume":"13","author":"AI Ramsingh","year":"2018","unstructured":"Ramsingh AI, Gray SJ, Reilly A, Koday M, Bratt D, Koday MT et al (2018) Sustained AAV9-mediated expression of a non-self protein in the CNS of non-human primates after immunomodulation. PLoS One 13(6):e0198154","journal-title":"PLoS One"},{"issue":"3","key":"10050_CR36","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.ymthe.2019.11.011","volume":"28","author":"JL Shirley","year":"2020","unstructured":"Shirley JL, Keeler GD, Sherman A, Zolotukhin I, Markusic DM, Hoffman BE et al (2020) Type I IFN Sensing by cDCs and CD4(+) T Cell Help Are Both Requisite for Cross-Priming of AAV Capsid-Specific CD8(+) T Cells. Mol Ther 28(3):758\u2013770","journal-title":"Mol Ther"},{"issue":"3","key":"10050_CR37","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","volume":"28","author":"JL Shirley","year":"2020","unstructured":"Shirley JL, de Jong YP, Terhorst C, Herzog RW (2020) Immune Responses to Viral Gene Therapy Vectors. Mol Ther 28(3):709\u2013722","journal-title":"Mol Ther"},{"issue":"1","key":"10050_CR38","doi-asserted-by":"publisher","first-page":"4251","DOI":"10.1038\/s41467-021-24524-8","volume":"12","author":"TS Pearson","year":"2021","unstructured":"Pearson TS, Gupta N, San Sebastian W, Imamura-Ching J, Viehoever A, Grijalvo-Perez A et al (2021) Gene therapy for aromatic L-amino acid decarboxylase deficiency by MR-guided direct delivery of AAV2-AADC to midbrain dopaminergic neurons. Nat Commun 12(1):4251","journal-title":"Nat Commun"},{"issue":"3\u20134","key":"10050_CR39","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1089\/hum.2022.163","volume":"34","author":"X Chen","year":"2023","unstructured":"Chen X, Lim DA, Lawlor MW, Dimmock D, Vite CH, Lester T et al (2023) Biodistribution of Adeno-Associated Virus Gene Therapy Following Cerebrospinal Fluid-Directed Administration. Hum Gene Ther 34(3\u20134):94\u2013111","journal-title":"Hum Gene Ther"},{"issue":"2","key":"10050_CR40","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ymthe.2019.11.012","volume":"28","author":"T Taghian","year":"2020","unstructured":"Taghian T, Marosfoi MG, Puri AS, Cataltepe OI, King RM, Diffie EB et al (2020) A Safe and Reliable Technique for CNS Delivery of AAV Vectors in the Cisterna Magna. Mol Ther 28(2):411\u2013421","journal-title":"Mol Ther"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-026-10050-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-026-10050-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-026-10050-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:21:43Z","timestamp":1792106503000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-026-10050-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10050"],"URL":"https:\/\/doi.org\/10.1007\/s10928-026-10050-x","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"6 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.A.C. is currently an employee at AbbVie Inc., USA. S.L. is currently an employee at Daiichi Sankyo. T.J., A.N., F.C., C.D., G.M.T, were employees of Astrazeneca, UK when this work was conducted.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"40"}}